You need to be logged in to see the full monograph.


Date of issue: September 2020, Version: 3

bumps logo
A corresponding patient information leaflet on USE OF PIZOTIFEN IN PREGNANCY is available.

Pizotifen is a sedating antihistamine with strong serotonin antagonist and weak antimuscarinic properties used in the prophylactic management of recurrent vascular headaches, migraines and cluster headaches. However, pizotifen is not effective in treating acute headache/migraine attacks.

The available data on pizotifen use in human pregnancy are extremely limited. Published data consist of a single case series of pizotifen-exposed pregnancies (n=12), from which there were no cases of major malformation. Unpublished national surveillance data collected by UKTIS include outcomes for 46 prospectively reported therapeutic pizotifen-exposed pregnancies, with first trimester exposure confirmed in 27 cases. Although these data do not signal that pizotifen is a major teratogen, the risk to the fetus following maternal use in pregnancy remains unknown.

Pizotifen use in pregnancy is therefore not routinely recommended unless compellingly indicated. Owing to the lack of published data regarding malformation risks, women who have been exposed to pizotifen in the first trimester are encouraged to attend their routine detailed fetal anomaly scan which is generally conducted at around 18 to 20 weeks of pregnancy.

Exposure to pizotifen at any stage in pregnancy would not usually be regarded as medical grounds for termination of pregnancy or any additional fetal monitoring. However, other risk factors may be present in individual cases which may independently increase the risk of adverse pregnancy outcome. Clinicians are reminded of the importance of consideration of such factors when performing case-specific risk assessments.

This is a summary of the full UKTIS monograph for health care professionals and should not be used in isolation. The full UKTIS monograph and access to any hyperlinked related documents is available to NHS health care professionals who are logged in.

If you have a patient with exposure to a drug or chemical and require assistance in making a patient-specific risk assessment, please telephone UKTIS on 0344 892 0909 to discuss the case with a teratology specialist.

If you would like to report a pregnancy to UKTIS please click here to download our pregnancy reporting form. Please encourage all women to complete an online reporting form.

Disclaimer: Every effort has been made to ensure that this monograph was accurate and up-to-date at the time of writing, however it cannot cover every eventuality and the information providers cannot be held responsible for any adverse outcomes of the measures recommended. The final decision regarding which treatment is used for an individual patient remains the clinical responsibility of the prescriber. This material may be freely reproduced for education and not for profit purposes within the UK National Health Service, however no linking to this website or reproduction by or for commercial organisations is permitted without the express written permission of this service. This document is regularly reviewed and updated. Only use UKTIS monographs downloaded directly from to ensure you are using the most up-to-date version.